437 related articles for article (PubMed ID: 27732330)
21. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
22. Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.
Liebich G; Lamy O; Aubry-Rozier B; Gonzalez-Rodriguez E
Bone; 2023 Jul; 172():116764. PubMed ID: 37062514
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
24. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
25. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
[TBL] [Abstract][Full Text] [Related]
27. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
28. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
29. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Cummings SR; Ferrari S; Eastell R; Gilchrist N; Jensen JB; McClung M; Roux C; Törring O; Valter I; Wang AT; Brown JP
J Bone Miner Res; 2018 Feb; 33(2):190-198. PubMed ID: 29105841
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
[TBL] [Abstract][Full Text] [Related]
31. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.
Anastasilakis AD; Polyzos SA; Makras P; Aubry-Rozier B; Kaouri S; Lamy O
J Bone Miner Res; 2017 Jun; 32(6):1291-1296. PubMed ID: 28240371
[TBL] [Abstract][Full Text] [Related]
32. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
[TBL] [Abstract][Full Text] [Related]
33. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
Endocrine; 2020 Sep; 69(3):516-518. PubMed ID: 32441026
[TBL] [Abstract][Full Text] [Related]
35. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
[TBL] [Abstract][Full Text] [Related]
36. [Multiple vertebral fractures after denosumab discontinuation].
Tjelum L; Eiken P
Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
[TBL] [Abstract][Full Text] [Related]
37. Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis.
Tsuchiya K; Ishikawa K; Tani S; Oshita Y; Kuroda T; Yamamura R; Emori H; Maruyama H; Matsuoka A; Kudo Y; Shirahata T; Toyone T; Nagai T; Inagaki K
Clin Interv Aging; 2019; 14():1445-1450. PubMed ID: 31496671
[TBL] [Abstract][Full Text] [Related]
38. Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report.
Koiwai H; Kamimura M; Nakamura Y; Takahashi J; Taguchi A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):178-181. PubMed ID: 33019908
[TBL] [Abstract][Full Text] [Related]
39. Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report.
Maezumi Y; Kamimura M; Nakamura Y; Takahashi J
Mod Rheumatol Case Rep; 2020 Jul; 4(2):218-221. PubMed ID: 33087002
[TBL] [Abstract][Full Text] [Related]
40. Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report.
Kashii M; Ebina K; Kitaguchi K; Yoshikawa H
Bone Rep; 2020 Dec; 13():100288. PubMed ID: 32548215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
